Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923032 | 0.88 | PTGDR2 (0.39) | PTGDR2MAPTPOLBPTGS2LMNA | |
| SCHEMBL12415747 | 0.86 | TLR7 (0.34) | ENPP1KMT2A | |
| SCHEMBL13236238 | 0.81 | MAPT (0.39) | PTGDR2MAPTPOLBPTGS2LMNA | |
| SCHEMBL12569022 | 0.80 | TBXA2R (0.44) | ENPP1PTGDR2MAPTPOLBPTGS2 | |
| SCHEMBL12568714 | 0.75 | TBXA2R (0.39) | ENPP1PTGDR2MAPTPOLBLMNA | |
| SCHEMBL2944286 | 0.75 | PTGDR2 (0.48) | PTGDR2MAPTPOLBNOS1ALDH1A1 | |
| SCHEMBL13236205 | 0.73 | NPSR1 (0.37) | L3MBTL1ALDH1A1KMT2AGAARAB9A | |
| SCHEMBL5959155 | 0.72 | POLB (0.39) | PTGDR2MAPTPOLBLMNANOS1 | |
| SCHEMBL13264578 | 0.72 | ALK (0.30) | L3MBTL1GAA | |
| SCHEMBL12568712 | 0.72 | POLB (0.41) | MAPTPOLBPTGS2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | ENPP1 156/4885PTGDR2 87/4885MAPT 2120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.